Several other equities research analysts have also recently weighed in on the stock. Leerink Swann reiterated a buy rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Cantor Fitzgerald reiterated a buy rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. HC Wainwright reiterated a buy rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Piper Jaffray Companies reiterated a buy rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Friday, October 27th. Finally, Zacks Investment Research upgraded shares of CymaBay Therapeutics from a sell rating to a hold rating in a research report on Monday, September 18th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. CymaBay Therapeutics has an average rating of Buy and a consensus price target of $14.50.
Shares of CymaBay Therapeutics (CBAY) traded up $0.28 during midday trading on Wednesday, reaching $9.91. 400,853 shares of the company’s stock traded hands, compared to its average volume of 572,659. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics has a 1 year low of $1.46 and a 1 year high of $10.25. The firm has a market cap of $434.69, a PE ratio of -9.81 and a beta of 1.82.
In related news, SVP Charles Mcwherter purchased 5,000 shares of CymaBay Therapeutics stock in a transaction on Thursday, November 2nd. The stock was acquired at an average cost of $8.67 per share, for a total transaction of $43,350.00. Following the completion of the acquisition, the senior vice president now owns 10,300 shares of the company’s stock, valued at approximately $89,301. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kurt Von Emster sold 173,192 shares of the firm’s stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $9.41, for a total transaction of $1,629,736.72. Following the completion of the sale, the director now owns 90,000 shares of the company’s stock, valued at $846,900. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 304,749 shares of company stock valued at $2,841,832. 15.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new stake in CymaBay Therapeutics in the third quarter worth $18,948,000. Vanguard Group Inc. grew its holdings in CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after purchasing an additional 170,126 shares during the period. Citadel Advisors LLC acquired a new stake in CymaBay Therapeutics in the third quarter worth $5,159,000. EAM Investors LLC acquired a new stake in CymaBay Therapeutics in the third quarter worth $4,788,000. Finally, Omega Fund Management LLC grew its holdings in CymaBay Therapeutics by 82.9% in the third quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after purchasing an additional 250,000 shares during the period. Institutional investors and hedge funds own 69.12% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Oppenheimer Analysts Give CymaBay Therapeutics (CBAY) a $15.00 Price Target” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.themarketsdaily.com/2018/01/12/oppenheimer-analysts-give-cymabay-therapeutics-cbay-a-15-00-price-target.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.